Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsJames B. Yu, MD, MHS, FASTRO
he/him/his
Assistant Professor AdjunctDownloadHi-Res Photo
About
Copy Link
Titles
Assistant Professor Adjunct
Biography
James Yu, MD, MHS, is Professor of Radiation Oncology and Genitourinary Cancers Radiotherapy Lead at Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire.
He is a former Professor of Radiation Oncology at the Yale School of Medicine, former Associate Chief Medical Officer of the Smilow Cancer Hospital and Care Centers and Executive Vice Chair of Columbia University Irving Medical Center Department of Radiation Oncology.
In his academic work, Dr. Yu conducts research on ways to use radiotherapy treatments to improve outcomes for cancer patients. “We need to push the field ever forward and not be satisfied with merely prolonging survival,” says Dr. Yu. “I think radiosurgery will play a role in this. As systemic therapies improve and our ability to control microscopically disseminated disease improves, noninvasive ablative therapies will become ever more important.”
As a former Yale Center for Clinical Investigation scholar and founding member of the Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale, Dr. Yu’s research centers on the comparative effectiveness of new radiation technologies and how these new technologies are adopted nationally.
Dr. Yu is the Editor-in Chief of JNCI Cancer Spectrum, Deputy Editor-In-Chief of the journal Practical Radiation Oncology and is on the editorial boards of the Journal of Clinical Oncology - Clinical Cancer Informatics, JNCI, Journal of Surgical Oncology, and Oncology (Williston Park), and former editorial board member of the Journal of Clinical Oncology.
He has published over 350 original manuscripts and co-edited the textbook Pocket Radiation Oncology and Principles of Clinical Cancer Research. He is the radiation oncology co-chair for the Southwest Oncology Group Genitourinary Cancers Committee, and a nationally recognized expert in patient reported outcomes.
Last Updated on March 10, 2025.
Appointments
Medical Oncology and Hematology
Assistant Professor AdjunctPrimary
Other Departments & Organizations
- Brain Tumor Center
- COPPER Center
- Gamma Knife Center
- Internal Medicine
- Medical Oncology and Hematology
- Pituitary Program
- Prostate & Urologic Cancers Program
- Radiation Oncology
- Yale Cancer Center
- Yale Ventures
- Yale-BI Biomedical Data Science Fellowship
Education & Training
- MHS
- Yale University, Masters of Health Science (2014)
- Resident
- Yale New Haven Hospital (2009)
- Chief Resident
- Yale School of Medicine (2009)
- Intern
- California Pacific Medical Center, San Francisco, CA (2005)
- MD
- University of Michigan Medical School (2004)
- BS
- Yale University (1999)
Research
Copy Link
Overview
Medical Research Interests
Breast Neoplasms; Central Nervous System Neoplasms; Head and Neck Neoplasms; Radiotherapy, Intensity-Modulated; Urogenital Neoplasms
ORCID
0000-0002-3119-3226
Research at a Glance
Yale Co-Authors
Frequent collaborators of James B. Yu's published research.
Publications Timeline
A big-picture view of James B. Yu's research output by year.
Research Interests
Research topics James B. Yu is interested in exploring.
Henry S. Park, MD, MPH
Cary P Gross, MD
Veronica Chiang, MD, FAANS
Sanjay Aneja, MD
Kenneth B. Roberts, MD
Lynn D. Wilson, MD, MPH, FASTRO
435Publications
4,486Citations
Breast Neoplasms
Radiotherapy, Intensity-Modulated
Head and Neck Neoplasms
Publications
2025
EPID-25. Molecular Epidemiology of Adult Diffuse Gliomas in the United States
Kinslow C, DeStephano D, Ostrom Q, Roy S, Yu J, Siegelin M, Horowitz D, Bruce J, Kachnic L, Hu J, Canoll P, Cheng S, Wang T, Neugut A. EPID-25. Molecular Epidemiology of Adult Diffuse Gliomas in the United States. Neuro-Oncology 2025, 27: v191-v191. PMCID: PMC12600394, DOI: 10.1093/neuonc/noaf201.0755.Peer-Reviewed Original ResearchConceptsIncidence rateNon-Hispanic white populationUS cancer registriesIncidence rate estimatesPopulation-based dataIncidence rate calculationsMolecular epidemiologyAdult-type diffuse gliomasEnd Results Program databaseThree-year survival ratePersons per yearCancer RegistryEpidemiology of gliomasIDH-mutant astrocytomasIDH-mutant tumorsIDH-wildtype glioblastomaIDH-wildtype gliomasIDH-mutant glioblastomasIDH-wildtype astrocytomasAsian/Pacific IslanderIDH-mutant gliomasMultiple imputationRisk estimatesWhite populationDiffuse gliomasRacial and Ethnic Diversity of the Oncology Workforce: Projections From 2020 to 2060
Roberts W, Soulos P, Herrin J, Pollack C, Genao I, Yu J, Boatright D, Gross C. Racial and Ethnic Diversity of the Oncology Workforce: Projections From 2020 to 2060. JCO Oncology Practice 2025, 21: 1877-1885. PMID: 41074755, DOI: 10.1200/op-25-00876.Peer-Reviewed Original ResearchCitationsAltmetricDiversity of the oncology physician workforce: Projections from 2020 to 2060.
Roberts W, Soulos P, Herrin J, Genao I, Yu J, Pollack C, Boatright D, Gross C. Diversity of the oncology physician workforce: Projections from 2020 to 2060. JCO Oncology Practice 2025, 21: 273-273. DOI: 10.1200/op.2025.21.10_suppl.273.Peer-Reviewed Original ResearchThe Comparative Toxicity of Focal Ablation vs. IMRT for Prostate Cancer
Yu J, DeStephano D, Jeffers B, Tward A, Spina C, Horowitz D, Wang T, Kachnic L, Soulos P, Gross C, Cheng S. The Comparative Toxicity of Focal Ablation vs. IMRT for Prostate Cancer. International Journal Of Radiation Oncology • Biology • Physics 2025 PMID: 40998272, DOI: 10.1016/j.ijrobp.2025.09.020.Peer-Reviewed Original ResearchAltmetricConceptsIntensity modulated radiation therapyFocal ablative therapyProstate cancerRadiation therapyGastrointestinal toxicityFT patientsRectal bleedingIMRT patientsHigher risk of incontinenceHigh riskAndrogen deprivation therapyStandard radiation therapyRisk of incontinenceMonths of treatmentSEER-Medicare databaseGenitourinary toxicityAndrogen deprivationGenitourinary complicationsAblation therapyFocal ablationIncontinence therapyTreatment modalitiesLogistic regression modelsCancer characteristicsSEER-MedicareAnaplastic Large Cell Lymphoma of the Breast by Race and Ethnicity
Kim D, Lowe L, Neugut A, Yu J, Cheng S, Kachnic L, Horowitz D, Rohde C, Kinslow C. Anaplastic Large Cell Lymphoma of the Breast by Race and Ethnicity. JAMA Network Open 2025, 8: e2528013. PMID: 40892414, PMCID: PMC12406062, DOI: 10.1001/jamanetworkopen.2025.28013.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsAge-adjusted incidence ratesAnaplastic large cell lymphomaPersons per yearIncidence rateLarge cell lymphomaT-cell lymphomaCohort studyPopulation-based cohort studyEstimates of incidence ratesAmerican IndiansPacific IslandersSurveillance, EpidemiologyCell lymphomaWhite patient populationPrimary anaplastic large cell lymphomaCases of T-cell lymphomaComplications associated with breast implantsAlaska NativesMain OutcomesWhite patientsBlack patientsBlack populationCohortPatient populationT cellsPower as an explanation for cancer disparities: a commentary on Krieger et al.
Hudson M, Yu J. Power as an explanation for cancer disparities: a commentary on Krieger et al. JNCI Cancer Spectrum 2025, 9: pkaf072. PMID: 40912682, PMCID: PMC12413224, DOI: 10.1093/jncics/pkaf072.Peer-Reviewed Original ResearchEvaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 for the treatment of extracranial oligometastatic non-small cell lung cancer with radiosurgery
Yu J, Corn B, Qureshi S, Jairam V, Yu L, Pendyala P, Riaz A, Ennis R, Sapir E. Evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 for the treatment of extracranial oligometastatic non-small cell lung cancer with radiosurgery. Practical Radiation Oncology 2025 PMID: 40865796, DOI: 10.1016/j.prro.2025.07.008.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerOligometastatic non-small cell lung cancerCell lung cancerESMO-MCBS v1.1ESMO-MCBSRadiation therapyClinical benefitEpidermal growth factor receptor-mutant non-small cell lung cancerLung cancerAmerican Society for Radiation Oncology (ASTROStereotactic body radiation therapyClinical research studiesStandard-of-care chemotherapyMagnitude of Clinical Benefit ScaleProgression-free survivalEpidermal growth factor receptorSingle-arm studyGrowth factor receptorEuropean SocietyQuality-of-life improvementAssociated with substantial improvementsOligometastatic diseaseStereotactic radiotherapyLocal therapyTargeted therapyLymphomas of the Breast After Postmastectomy Implant-Based Breast Reconstruction
Kinslow C, Kim D, Lowe L, Cheng S, Yu J, Kachnic L, Rohde C, Horowitz D, Neugut A. Lymphomas of the Breast After Postmastectomy Implant-Based Breast Reconstruction. JAMA Network Open 2025, 8: e2525820. PMID: 40773200, PMCID: PMC12332618, DOI: 10.1001/jamanetworkopen.2025.25820.Peer-Reviewed Original ResearchAltmetric30 year trends in racial disparities for early stage lung cancer treatment.
Lynch O, Lee D, Soulos P, Yu J, Herrin J, Gross C. 30 year trends in racial disparities for early stage lung cancer treatment. Journal Of Clinical Oncology 2025, 43: 1599-1599. DOI: 10.1200/jco.2025.43.16_suppl.1599.Peer-Reviewed Original ResearchConceptsReceipt of curative therapyReceipt of curative treatmentCurative therapyCurative treatmentLung cancer treatmentWhite patientsBlack patientsReceipt of treatmentRacial disparitiesBlack-white differencesStage I-II NSCLCEarly stage lung cancerCancer treatmentStage lung cancerYears prior to diagnosisMedicare beneficiariesMonths of diagnosisRetrospective cohort studyMultivariate logistic regressionAssessed temporal trendsNon-LatinxProbability of treatmentPredictive probability of treatmentSEER-MedicareLung cancerPractical Considerations for the Treatment of Primary Renal Cell Carcinoma With SABR
Yu J, Grew D, Sculley E, Siva S, Hardcastle N, Tang C, Yang J, Kim M, Lo S. Practical Considerations for the Treatment of Primary Renal Cell Carcinoma With SABR. Practical Radiation Oncology 2025, 15: 625-631. PMID: 40323243, DOI: 10.1016/j.prro.2025.03.007.Peer-Reviewed Original ResearchCitationsAltmetric
Academic Achievements & Community Involvement
Copy Link
Honors
honor Fellow
07/17/2023National AwardAmerican Society for Radiation OncologyDetailsUnited Stateshonor Cancer Prevention and Control Research Prize
12/31/2017Yale School of Medicine AwardYale Cancer CenterDetailsUnited Stateshonor Population Research Prize
11/22/2013Yale School of Medicine AwardYale Cancer CenterDetailsUnited Stateshonor Seattle Prostate Brachytherapy Fellow
01/01/2009National AwardAmerican Brachytherapy SocietyDetailsUnited Stateshonor Roentgen Resident Research Award
01/01/2008National AwardRSNADetailsUnited States
News
Copy Link
News
Get In Touch
Copy Link
Contacts
Email